Free Trial
NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

Glaukos logo
$87.45 +2.96 (+3.50%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$85.42 -2.03 (-2.32%)
As of 10/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Glaukos Stock (NYSE:GKOS)

Advanced

Key Stats

Today's Range
$83.88
$88.50
50-Day Range
$79.95
$96.54
52-Week Range
$77.10
$163.71
Volume
882,896 shs
Average Volume
852,350 shs
Market Capitalization
$5.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$122.00
Consensus Rating
Moderate Buy

Company Overview

Glaukos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

GKOS MarketRank™: 

Glaukos scored higher than 92% of companies evaluated by MarketBeat, and ranked 87th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Upside Potential

    Glaukos has a consensus price target of $122.00, representing about 39.5% upside from its current price of $87.45.

  • Amount of Analyst Coverage

    Glaukos has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Glaukos' stock forecast and price target.
  • Earnings Growth

    Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Glaukos is -53.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Glaukos is -53.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Glaukos has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Glaukos' valuation and earnings.
  • Percentage of Shares Shorted

    5.63% of the outstanding shares of Glaukos have been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 4.72%, indicating that investor sentiment is improving.
  • Dividend Yield

    Glaukos does not currently pay a dividend.

  • Dividend Growth

    Glaukos does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.63% of the outstanding shares of Glaukos have been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 4.72%, indicating that investor sentiment is improving.
  • News Sentiment

    Glaukos has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Glaukos this week, compared to 8 articles on an average week.
  • Search Interest

    10 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Glaukos to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Glaukos insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.80% of the stock of Glaukos is held by insiders.

  • Percentage Held by Institutions

    99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Glaukos' insider trading history.
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Now Covered by Analysts at The Goldman Sachs Group
Front-Run Buffett's Shocking Gold Move
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.tc pixel
Glaukos initiated with a Buy at Goldman Sachs
See More Headlines

GKOS Stock Analysis - Frequently Asked Questions

Glaukos' stock was trading at $149.94 on January 1st, 2025. Since then, GKOS stock has decreased by 41.7% and is now trading at $87.4460.

Glaukos Corporation (NYSE:GKOS) announced its earnings results on Wednesday, July, 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company's quarterly revenue was up 29.7% on a year-over-year basis.
Read the conference call transcript
.

Glaukos (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos' top institutional investors include GAMMA Investing LLC. Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends
.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2025
Today
10/04/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:GKOS
CIK
1192448
Employees
780
Year Founded
1998

Price Target and Rating

High Price Target
$165.00
Low Price Target
$72.00
Potential Upside/Downside
+39.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$146.37 million
Net Margins
-21.43%
Pretax Margin
-21.28%
Return on Equity
-8.59%
Return on Assets
-6.61%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
5.51
Quick Ratio
4.69

Sales & Book Value

Annual Sales
$383.48 million
Price / Sales
13.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.91 per share
Price / Book
6.29

Miscellaneous

Outstanding Shares
57,350,000
Free Float
54,024,000
Market Cap
$5.02 billion
Optionable
Optionable
Beta
0.76

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:GKOS) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners